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We erroneously reported that the studies byWilliams et al. (2006 and 2007) were performed in a mouse model for CML, which shows
a favorable clinical response to imatinib treatment. In fact, their studies addressed the role of the p19ARF locus in BCR/ABL-driven
ALL, which shows a poor response to treatment with imatinib.We sincerely apologize for this inaccuracy but feel compelled to inform
the reader of our mistake.
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